Summary
The dopamine (DA) autoreceptor agonist (−)-3PPP (preclamol) was tested in male schizophrenic volunteers for safety. The drug was administered intramuscularly in a single rising dose design, crossed with a similar “rising dose” placebo period; all evaluations and raters were blind to drug or placebo administration. Pharmacokinetic, endocrine, safety, and mental status outcome measures were completed before and after each single dose of drug or placebo. Pharmacokinetic analysis showed blood levels between 200–500 pmoles/ml after the intramuscular drug doses of 30–40 mg. Drug half life is 2–2.5 hrs. Growth hormone (GH) levels were elevated in a linear fashion to the 30 mg dose; whereafter, the drug failed to affect GH at all. All safety evaluations were negative, including any untoward effects on the major organ systems. After single dose drug administration, evidence of antipsychotic action occurred in two of the four subjects. This study suggests that (−)-3PPP/preclamol is a safe drug for study in the treatment of schizophrenia and may have antipsychotic efficacy.
Similar content being viewed by others
References
Andreasen N (1982) Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 39: 784–788
Arnt J, Christensen AV, Hyttel J, Larsen J-J, Svendsen O (1983) Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity. Eur J Pharmacol 86: 185–198
Baldessarini RJ (1991) S(+)Aporphines as potential limbic-selective antipsychotic agents. Presented at the International Congress on Schizophrenia Research, Tucson, Arizona
Bergstrom DA, Carlson JH, Bromley SD, Jackson DM, Walters JR (1986) Differential electrophysiological effects of 3-PPP and its enantiomers on dopamine autoreceptors and postsynaptic receptors. Eur J Pharmacol 13: 124(1–2): 75–84
Carlsson A, Lindqvist M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20: 140–145
Clark D, Hjorth S, Carlsson A (1985a) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 62: 1–52
Clark D, Hjorth S, Carlsson A (1985b) Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J Neural Transm 62: 171–207
Corsini GU, Del Zompo M, Manconi S, Cianchetti C, Mangoni A, Gessa GL (1977) Sedative, hypnotic and antipsychotic effects of low doses of apomorphine in man. Adv Biochem Psychopharmacol 16: 645–648
Corsini GU, Pitzalis GF, Bernardi F, Bocchetta A, Del Zompo M (1981) The use of dopamine agonists in the treatments of schizophrenia. Neuropharmacology 20: 1309–1313
Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192: 481–483
Ferrier EC, Johnstone EC, Crow TJ (1984) Clinical effects of apomorphine in schizophrenia. Br J Psychiatry 144: 341–348
Frohman LA, Stachura ME (1975) Neuropharmacologic control of neuroendocrine function in man. Metabolism 24: 211–234
Hjorth S, Carlsson A, Clark D, Svensson K, Wikström H, Sanchez D, Lindberg P, Hacksell U, Arvidsson L-E, Johansson A, Nilsson JLG (1983) Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacology 81: 89–99
Klein DF, Davis JM (1969) Review of antipsychotic drug literature. Diagnosis and drug treatment of psychiatric disorders. Williams and Wilkins, Baltimore, pp 61–63
Levy MI, Davis BM, Mohs RC, Kendler KS, Mathe AA, Trigos G, Horvath TB, Davis KL (1984) Apomorphine and schizophrenia: treatment, CSF, and neuroendocrine responses. Arch Gen Psychiatry 41: 520–524
Magnusson T, Carlsson A, Lindberg P, Sanchez D (1983) Evidence for activation of dopaminergic autoreceptors by (−)-3-PPP. Acta Pharmaceut Suec 1: 16–18
Overall JE, Gorham DR (1962) The Brief Psychiatric Rating Scale. Psychol Reports 10: 799–812
Svensson L, Ahlenius S (1983) Suppression of exploratory locomotor activity in the rat by the local application of (−)3-PPP into the nucleus accumbens. Eur J Pharmacol 88: 393–397
Tamminga CA, Schaffer MH, Smith RC, Davis JM (1978) Schizophrenic symptoms improve with apomorphine. Science 200: 567–568
Tamminga CA, Gotts MD, Thaker GK, Alphs LD, Foster NL (1986) Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry 43: 398–402
Walinder J, Skott A, Carlsson A, Roos BE (1976) Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. Arch Gen Psychiatry 33: 501–505
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tamminga, C.A., Cascella, N.G., Lahti, R.A. et al. Pharmacologic properties of (−)-3PPP (preclamol) in man. J. Neural Transmission 88, 165–175 (1992). https://doi.org/10.1007/BF01244730
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01244730